Physician profile
Robert C Owen
NPI 1336121649
$493.64
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $64.83 · 2021: $66.68 · 2022: $249.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $95.20 | 2022 | |
| Stryker Corporation | $92.11 | 2019-2022 | |
| Alk-Abello, INC | $88.82 | 2020-2022 | |
| Glaxosmithkline, LLC. | $62.09 | 2022 | |
| Olympus America INC. | $28.34 | 2019-2020 | |
| Integra Lifesciences Corporation | $24.94 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.31 | 2022 | |
| Intersect Ent, INC. | $19.76 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.06 | 2019 | |
| Optinose US, INC. | $15.31 | 2020 | |
| Merck Sharp & Dohme LLC | $12.61 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Owen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.